Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Jan 20 (Reuters) - Novavax said on Tuesday it has entered into a licensing agreement with Pfizer to develop vaccine ...
Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...
Programmable nucleic acid nanoparticles boost vaccine immune responses as effectively as standard adjuvants in mice while ...
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized ...
A newly developed nanoparticle-based vaccine successfully prevented melanoma, pancreatic, and triple-negative breast cancers in mice. The corresponding study was published in Cell Reports Medicine.
Looking back on therapeutics stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Novavax (NASDAQ:NVAX) and its peers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback